Combining cyclization and mirror-image amino acids transformed a fragile antimicrobial peptide into a stable, potent drug candidate that killed MDR bacteria in mice with no toxicity.
Zero toxicity, full clearancePT-17 significantly reduced MDR E. coli bacterial loads in mouse organs with no detectable toxicity — demonstrating both efficacy and safety in a preclinical infection model
What the researchers found
By combining cyclization (closing the peptide into a ring) and D-amino acid substitution (using mirror-image amino acids), researchers transformed a linear antimicrobial peptide called P-07 into PT-17 — a dramatically more stable version that resists enzymatic breakdown. PT-17 retained broad-spectrum killing activity against multidrug-resistant (MDR) bacteria, showed a high therapeutic index (meaning it kills bacteria at much lower concentrations than those toxic to human cells), disrupted bacterial membranes rapidly, showed low potential to trigger resistance, and worked synergistically with conventional antibiotics. In mice infected with MDR E. coli, PT-17 significantly reduced bacterial loads in major organs with no detectable toxicity.
Why it matters
Antibiotic resistance is a global crisis, and antimicrobial peptides (AMPs) represent one of the most promising alternatives to conventional antibiotics. However, natural AMPs are rapidly destroyed by enzymes in the body. This study demonstrates that two stabilization strategies — cyclization and D-amino acid substitution — can be combined to make β-turn AMPs dramatically more stable without sacrificing their ability to kill resistant bacteria. This provides a practical blueprint for turning promising lab peptides into viable drug candidates.
The numbers in context
PT-17 lead candidate · Broad-spectrum activity against MDR pathogens · High therapeutic index · Significant reduction of MDR E. coli in mouse organs · Synergy with conventional antibiotics · No detectable toxicity in mice
How the study worked
Starting from a linear β-turn antimicrobial peptide (P-07), the researchers created multiple cyclized derivatives using disulfide bonds and lactam bonds, plus versions with D-amino acid substitutions. They tested stability against enzymatic degradation, antimicrobial activity against MDR bacteria, membrane disruption speed, resistance development potential, and synergy with existing antibiotics. The lead compound PT-17 was then tested in a mouse infection model using MDR E. coli.
Who was studied
In vitro against MDR bacterial pathogens; in vivo mouse infection model with MDR E. coli
What this study cannot tell us
This is preclinical research — no human trials have been conducted. The mouse infection model, while informative, may not fully predict clinical performance. Specific MIC values and quantitative organ bacterial load reductions were not detailed in the abstract. Manufacturing scalability and cost of the cyclized peptide are not addressed. Long-term safety data are not available.
How to read the evidence
This is a preclinical study published in the Journal of Medicinal Chemistry, a top-tier medicinal chemistry journal. It includes both in-vitro activity data and in-vivo mouse efficacy data, providing solid proof of concept. However, no human safety or efficacy data exist yet.
When this study was published
Published in 2026, this is cutting-edge antimicrobial peptide research addressing one of the field's central challenges — enzymatic stability — with a practical combinatorial approach.
The bigger picture
With antibiotic resistance projected to kill 10 million people per year by 2050, antimicrobial peptides are among the most actively explored alternatives. The central challenge has always been stability — the body breaks peptides down too fast. This study solves that problem for an underexplored class of peptides (β-turn AMPs) using a combination strategy that could be broadly applied. The demonstration that PT-17 works synergistically with existing antibiotics is particularly promising, as combination therapy could revive the effectiveness of drugs that bacteria have become resistant to.
Questions still open
- Can the cyclization plus D-amino acid strategy be applied to other classes of antimicrobial peptides to create a broader pipeline?
- What is the manufacturing cost of PT-17, and is large-scale production feasible for clinical use?
- Would PT-17 remain effective against bacteria that develop resistance to membrane-disrupting peptides over time?
Common questions
Why can't we just use natural antimicrobial peptides as antibiotics?
Could bacteria become resistant to peptide antibiotics?
Read the original research
Overcoming Proteolytic Instability in a β-Turn Antimicrobial Peptide via Cyclization and Stereochemical Inversion to Combat MDR Bacteria.
Journal of medicinal chemistry, 69(4), 4726-4744
Citation
Wang, Taoran; Tian, Long; Zeng, Jiangmin; Ning, Ziyao; Zhang, Li; Zhao, Chunhui; Jiang, Shuyuan; Zeng, Chunlan; Han, Jiaqi; Luan, Liang; Ye, Weifeng; Meng, Qingbin. (2026). Overcoming Proteolytic Instability in a β-Turn Antimicrobial Peptide via Cyclization and Stereochemical Inversion to Combat MDR Bacteria.. Journal of medicinal chemistry, 69(4), 4726-4744. https://doi.org/10.1021/acs.jmedchem.5c03372